✓ Translated by DotMD AI Clinical Council Source: Circulation journal : official journal of the Japanese Circulation Society • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #22076422 ↗

Randomized Controlled Trial: Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study

Original Paper Title: “Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Dual lipid-lowering therapy starts atherosclerosis regression, but does not lead to significant changes in plaque composition. The continuous shift in plaque from fibro and fibro-fatty to necrotic with calcification was present in both groups.
  • Study Design & Sample: Randomized Controlled Trial published in Circulation journal : official journal of the Japanese Circulation Society (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Circulation journal : official journal of the Japanese Circulation Society (2012), this randomized controlled trial evaluating human clinical outcomes investigated: There is no study focusing on changes in coronary atherosclerosis during dual lipid-lowering therapy with statin and ezetimibe. Key clinical takeaway: Dual lipid-lowering therapy starts atherosclerosis regression, but does not lead to significant changes in plaque composition. The continuous shift in plaque from fibro and fibro-fatty to necrotic with calcification was present in both groups.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Circulation journal : official journal of the Japanese Circulation Society, 2012-01-15; Randomized Controlled Trial; Rigor 82/100): Dual lipid-lowering therapy starts atherosclerosis regression, but does not lead to significant changes in plaque composition. The continuous shift in plaque from fibro and fibro-fatty to necrotic with calcification was present in both groups.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: atorvastatin-calcium → Rx: atorvastatin-calcium-film-coated → Rx: ezetimibe → Rx: ezetimibe-and-simvastatin → Condition: atherosclerosis → Condition: cholesterol → Condition: coronary-artery-disease →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 22076422: Randomized Controlled Trial: Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study

3 of 3 Free Questions Remaining